Results 101 to 110 of about 55,011 (304)
JPGN Reports, EarlyView.Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker +3 more
wiley +1 more source
Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists [PDF]
, 2019 Dimitrios Patoulias +4 more
openalex +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching +2 more
wiley +1 more source
Effect of Lixisenatide (Short-acting Glucagon-Like Peptide 1 Receptor Agonist) as an Add-on to Insulin in Lowering HbA1C among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]
, 2023 Ashwaq Ali Abusalem, Ahmad Raja Albalawi
openalex +1 more source
Metformin Versus GLP-1 for Therapeutic Potential in Polycystic Ovary Syndrome [PDF]
Purpose: When patients with polycystic ovary syndrome fail conservative options for weight loss, utilizing medications such as metformin and glucagon-like peptide-1 receptor agonists may be considered. Metformin has been the first line agent for treating
Stone, Carlyn
core +1 more source
A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs [PDF]
, 2017 Background: Diabetes mellitus is a metabolic disorder defined by high blood glucose. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a newer class of medications that offer potential 2 to 3 kg weight loss and a 1% to 1.5% decrease in A1c.
Beutel Darrow, Shelby L.
core +1 more source
Impact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes
The Laryngoscope, EarlyView.ABSTRACT Objective The effectiveness of hypoglossal nerve stimulation (HGNS) for residual obstructive sleep apnea (OSA) in patients with prior bariatric surgery (BS) has not been previously reported. We evaluate and compare HGNS outcomes in this unique population.
Praneet C. Kaki +9 more
wiley +1 more source
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Journal of Diabetes Investigation, 2019 Today, glucagon‐like peptide‐1 (GLP‐1) receptor agonists are established glucose‐lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin ...
Bo Ahrén
doaj +1 more source
Obesity, EarlyView.ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source
npj Systems Biology and ApplicationsGlucagon-like peptide-1 (GLP-1) is a hormone known for its critical functions in managing blood sugar and offering cardiovascular benefits. Our study focuses on Glucagon Like Peptide 1 Receptor (GLP1R) agonists that act beyond glycemic control in ...
Zofia Wicik +7 more
doaj +1 more source